Influence of inhibition of the metabolic activation on the mutagenicity of some nitrosamines, triazenes, hydrazines and seniciphylline in Drosophila melanogaster.
It is determined to what extent certain inhibitors of the xenobiotic metabolizing enzyme systems have an influence on the mutagenicity of various pro-mutagens in Drosophila. 1-Phenylimidazole (PhI) is used as an inhibitor of the cytochrome P-450 (P-450) mediated monooxygenase activities. Iproniazid (Ipr) is a typical monoamine oxidase (MAO) inhibitor which as well seems capable of inhibiting to a certain extent P-450 mediated metabolism. N, N-Dimethyl benzylamine (N, N-DMB) is used as a competitive substrate for the N-oxidizing flavin-containing dimethylaniline monooxygenase (FDMAM). The enzyme-inhibiting activities of PhI and Ipr were determined in vitro using microsomes obtained from Drosophila larvae and adults. Both compounds were capable of inhibiting benzo[a]pyrene (BP) hydroxylation and p-nitroanisole (p-NA) demethylation, although for Ipr 100-fold higher concentrations were required compared to PhI. As model-mutagens were used: the nitrosamines dimethylnitrosamine (DMN) and diethylnitrosamine (DEN), the triazenes 1-(2,4,6-trichlorophenyl)-3,3-dimethyltriazene (Cl3PDMT), 1-(3-pyridyl)-3,3-dimethyltriazene (PyDMT) and dacarbazine (DTIC), the hydrazines procarbazine (PCZ), 1,1-dimethylhydrazine (1,1-DMH) and 1,2-dimethylhydrazine (1,2-DMH) as well as the pyrrolizidine alkaloid seniciphylline (SPh). Simultaneous or pretreatment with Ipr results in a clear decrease of the mutagenicity of Cl3PDMT, while PhI pretreatment leads to an increased mutagenicity. This indicates that these two inhibitors do not inhibit the same enzyme or isozyme. For SPh too, Ipr pretreatment results in some decrease of the mutagenicity. This is in contrast to DEN, where the activation is clearly inhibited by PhI while Ipr has only a minor effect. For DMN, DTIC and PCZ both Ipr and PhI pretreatment caused considerable decreases of the mutagenicity. Inhibition of the FDMAM catalyzed activity by N,N-DMB resulted in an increase of mutagenicity with Cl3PDMT, in a moderate decrease of mutagenicity with DTIC, and a marked decrease with DMN, which was strongly inhibited. In contrast to the clear-cut mutagenicity of PCZ, 1,1-DMH and 1,2-DMH are not mutagenic in Drosophila. No change was observed upon inhibition of the various metabolizing activities. Apart from using strain differences in metabolizing activities and enzyme induction, enzyme inhibition can also be used to determine the influence of metabolism on the in vivo mutagenicity of promutagens in Drosophila.
D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D001711:Biotransformation / Q000187:drug effects*; D065607:Cytochrome P-450 Enzyme Inhibitors; D004331:Drosophila melanogaster / Q000187:drug effects* / Q000235:genetics; D007093:Imidazoles / Q000494:pharmacology*; D007490:Iproniazid / Q000494:pharmacology*; D008861:Microsomes / Q000378:metabolism; D009152:Mutagenicity Tests; D009602:Nitrosamines / Q000493:pharmacokinetics* / Q000633:toxicity; D010105:Oxygenases / Q000037:antagonists & inhibitors; D011763:Pyrrolizidine Alkaloids / Q000493:pharmacokinetics* / Q000633:toxicity; D014227:Triazines / Q000493:pharmacokinetics* / Q000633:toxicity
D000814:Aniline Compounds; D065607:Cytochrome P-450 Enzyme Inhibitors; D007093:Imidazoles; D009602:Nitrosamines; D011763:Pyrrolizidine Alkaloids; D014227:Triazines; C013678:seneciphylline; C037738:1-phenylimidazole; C015157:N,N-dimethylaniline; D007490:Iproniazid; D010105:Oxygenases; C020066:dimethylaniline monooxygenase (N-oxide forming)